By the end of that 18-month study, patients in the placebo group scored on average 1.66 points worse than their performance at baseline on a standard dementia test...
Lecanemab targets the underlying issue of amyloid build-up in the brain, potentially changing the disease's course.
[
add
]
[
|
|
...
]